Randomised placebo controlled trial on the safety and efficacy of a topical treatment for bilaternal chronic plaque psoriasis in adults

H BioJuven Pty Ltd (Australia)0 个研究点目标入组 29 人开始时间: 2005年9月21日最近更新: 2015年1月13日

试验速览

暂无简介。

•1. Participants with mild to moderate, bilateral symmetric, chronic plaque type psoriasis
•2. In good general health and adequate venous access
•3. Participants of childbearing age who agree to continue using birth control measures for the duration of the study
•4. Males and Females between 18 and 75 years

•1. Chronic plaque psoriasis involving more than 60% of the body surface
•2. Pustular or generalized erythrodermic psoriasis
•3. Use of medications which affect psoriasis during the study (e.g. systemic therapy including retinoids, methotrexate, cyclosporine, or corticosteroid and non corticosteroid topical therapy, including vitamin D analogues, tazarotene, tacrolimus)
•4. Systemic therapy for psoriasis within 30 days of baseline
•5. UV light therapy within 21 days of baseline
•6. Topical corticosteroids within 14 days of baseline
•7. Liver function tests greater than 3 times the upper limit of normal at baseline
•8. Female participants who are lactating, pregnant or planning to become pregnant
•9. Participants have participated in another clinical trial in the last 30 days
•10. Participants unwilling to comply with study protocol
•11. Any other condition, which in the opinion of the investigators could compromise the study

发起方

H BioJuven Pty Ltd (Australia)